paroxetine
Commercial- Indications
- Depression, Anxiety, PMDD
Company intelligence / Profile preview
Skyepharma
Saint Quentin Fallavier, Auvergne-Rhône-Alpes, Franceskyepharma.com ↗
- Ownership
- Private
- Employees
- ~180
- Development stage
- Commercial
01
Overview
As a CDMO, clinical results pertain to client products manufactured or formulated using its technologies. The company has supported numerous approved drugs globally with its modified-release and complex oral dosage form expertise. Its facilities are FDA-, EU-, ANVISA-, and Korean MFDS-approved.
- Therapeutic areas
- PulmonologyCardiovascularNeurologyImmunology
- Modalities
- Small moleculeModified-release oral solid dosage forms
- Industry
- Contract Manufacturing Organization
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Skyepharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skyepharma.